Table 1.

Literature review of low-grade and high-grade gliomas treated with combination therapy with BRAF/MEKi or monotherapy with BRAFi.

Citation	Age (years)	Sex	Diagnosis	WHO grade	Line of therapy	Treatment	Best response	Rx duration (months)
Patient case #1	21	F	Ganglioglioma	I	2nd	Dabraf+tramet	SD	14 a
Del Bufalo et al 20	2.5	M	Ganglioglioma	I	2nd	Vemuraf	PR	54
Del Bufalo et al 20	4.5	NR	Ganglioglioma	I	1st	Vemuraf	CR	40
Aguilera et al 22	8	M	Ganglioglioma	I	1st	Vemuraf	PR	14 a
Del Bufalo et al 20	7.4	NR	Ganglioglioma	I	1st	Vemuraf	SD	13
Chamberlain et al 23	45	M	Ganglioglioma	I	2nd	Dabraf	PR	10
Lassaletta et al 24	2 mo	F	Hypothalamic chiasmatic glioma	I	2nd	Dabraf	PR	10
Chamberlain et al 23	34	M	Ganglioglioma	I	2nd	Dabraf	SD	7
Chamberlain et al 19	26	F	Ganglioglioma	I	2nd	Dabraf	SD	4
Del Bufalo et al 20	1 mo	NR	Ganglioneurocytoma	I	1st	Vemuraf	PD	3
Del Bufalo et al 20	10	NR	Ganglioglioma	I	1st	Vemuraf	Insuf. F/up	2
Del Bufalo et al 20	9	NR	PXA	II	1st	Vemuraf	PR	30
Chamberlain et al 19	53	M	PXA	II	3rd	Vemuraf	PR	10
Chamberlain et al 19	47	F	PXA	II	3rd	Vemuraf	SD	6
Chamberlain et al 19	34	F	PXA	II	3rd	Vemuraf	SD	4
Usubalieva et al 21	35	F	PXA	II	1st	Dabraf	PR	3
Patient case #2	19	M	Anaplastic PXA	III	2nd	Dabraf+tramet	SD	35 a
Toll et al 8	4	F	Anaplastic ganglioma	III	1st	Dabraf+tramet	PR	23 a
Brown et al 11	21	F	Anaplastic PXA	III	1st	Dabraf+tramet	PR	22 a
Toll et al 11	13	M	Anaplastic astroblastoma	III	2nd	Dabraf+tramet	CR	20
Brown et al 11	48	F	Anaplastic PXA	III	4th	Dabraf+tramet	PR	8 a
Smith-Cohn et al 26	23	F	Anaplastic PXA	III	2nd	Dabraf+tramet	PR	3
Burger et al 15	24	M	Anaplastic PXA	III	2nd	Dabraf	CR	27 a
Bautista et al 17	1.5	F	Anaplastic ganglioma	III	5th	Vemuraf	PR	20 a
Burger et al 15	50	M	Anaplastic PXA	III	3rd	Dabraf	PR	8 a
Bautista et al 17	6	M	Anaplastic ganglioma	III	2nd	Vemuraf	PR	3
Lee et al 18	41	M	Anaplastic PXA	III	2nd	Vemuraf	PR	3 a
Leaver et al 16	39	M	Anaplastic PXA	III	1st	Vemuraf	PR	2
Chamberlain et al 19	43	M	Anaplastic PXA	III	3rd	Vemuraf	PD	2
Bautista et al 17	9	F	Anaplastic astrocytoma	III	4th	Vemuraf	PD	0.5
Patient case #4	33	F	Epithelioid GBM	IV	2nd	Dabraf+tramet	SD	53 a
Toll et al 8	12	F	HGG with epithelioid morphology	IV	2nd	Dabraf+tramet	PR	32 a
Johanns et al 9	28	F	Epithelioid GBM	IV	1st	Dabraf+tramet	PR	11
Patient case #3	21	F	Epithelioid GBM	IV	2nd	Dabraf+tramet	SD	16 a
Woo et al 10	22	F	Epithelioid GBM	IV	1st	Dabraf+tramet	PR	7
Woo et al 10	22	F	Epithelioid GBM	IV	1st	Vemuraf+cobimet	SD	5.5
Johanns et al 9	24	M	Epithelioid GBM	IV	2nd	Dabraf+tramet	PR	3 b
Smith-Cohn et al 26	47	M	Epithelioid GBM	IV	3rd	Dabraf+tramet	PD	1
Beba Abadal et al 12	34	F	GBM	IV	3rd	Vemuraf	SD	11
Ceccon et al 13	27	M	Epithelioid GBM	IV	4th	Dabraf	SD	10
Robinson et al 14	9	M	Epithelioid GBM	IV	3rd	Vemuraf	PR	6 a
Burger et al 15	25	M	Glioblastoma, IDH-wt	IV	3rd	Dabraf	PR	3 a
Leaver et al 16	26	M	Epithelioid GBM	IV	1st	Vemuraf	PD	0.5

^aTreatment ongoing

^bNon-adherent to treatment.

Abbreviations: F = female, M = male, GBM = glioblastoma, PXA = pleomorphic xanthoastrocytoma, Dabraf = dabrafenib, dabraf+tramet = dabrafenib/trametinib, vemuraf = vemurafenib, vemuraf+vobemet = vemurafenib/vobimetinib, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NR = not reported, insuf. f/up = insufficient follow-up.

Keywords searched: glioma, primary brain tumor, BRAF, MEK, targeted, vemurafenib, dabrafenib, encorafenib, cobimetinib, trametinib, and binimetinib (Date range: January 2000 to December 2019).